Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in Pediatric Patients With Atopic Dermatitis (Open-Label Extension)
NCT02612454Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Oct 2015
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 3 trial of dupilumab in atopic dermatitis (AD), sponsored by Regeneron Pharmaceuticals. Started Oct 2015; status: completed.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT02612454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02612454.